Flurry of probes target insulin drugmakers and pharma middlemen

Insulin makers Eli Lilly, Novo Nordisk, Sanofi, and PBM CVS Health are targets in state investigations in Washington, Minnesota, and New Mexico. Attorneys general in those states are sharing information with Florida and California, according to various corporate financial filings. State and federal prosecutors appear to be looking into potentially anti-competitive business dealings that critics have leveled at this more than $20 billion niche market of the pharmaceutical industry, including whether drugmakers and middlemen in the supply chain have allowed prices to escalate in order to increase their profits. At the same time, class-action lawyers are bringing suits on behalf of patients. The price of insulin has reached record highs as Eli Lilly, Novo Nordisk, and Sanofi raised prices more than 240% over the past decade to often over $300 a vial today, with price rises frequently in lockstep, according to information technology firm Connecture.

Read more here

Kaiser Health News

By Sarah Jane Tribble